Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy

NCT ID: NCT04362735

Last Updated: 2020-04-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-08-01
• Study Completion Date: 2021-04-01

Brief Summary

INTRODUCTION: Vedolizumab is a gut selective anti-integrin agent which binds to the alfa4beta7 integrin, preventing its coupling to the endothelial MadCAM-1. It reduces leucocyte trafficking from the endothelium consequently reducing intestinal tissue inflammation. There is scarce evidence on the use of vedolizumab in CD in Brazil, mostly in patients with no previous biological therapy, where the drug seems to have a more adequate therapeutic potential.

Tha primary aim of the study is to analyze clinical remission rates at weeks 12, 26 and 52, and at last follow-up on naive CD patients submitted to vedolizumab therapy. Secondary outcomes will be clinical response rates at weeks 12, 26 and 52, and at last follow-up; endoscopic remission rates in colonoscopies performed; persistence of drug therapy over time; adverse events during treatment with vedolizumab and rates of abdominal surgery during therapy.

METHODS: A retrospective, longitudinal, observational study will be performed with patients with CD who used Vedolizumab at any time of their treatment as the first biologic option, after failure of conventional therapy. Following the induction dose of 300 mg at weeks 0, 2 and 6, and maintenance of 300 mg every 8 weeks, patients will be followed up to 52 weeks (1 year) or more (last follow-up captured). Records of the clinical evaluations at week 12, 26 and 52, and last follow-up, will be checked according to the HBI and PGA to define clinical response or clinical remission. Colonoscopies will also be checked to evaluate mucosal healing. Electronic charts will be reviewed also to analyze adverse events and surgery during therapy.

Detailed Description

INTRODUCTION: Inflammatory bowel diseases (IBD) are a group of chronic, idiopathic and immune-mediated diseases, mainly represented by Crohn's disease (CD) and Ulcerative Colitis (UC). There is a broad therapeutic spectrum according to the degree of disease activity, extension and behavior, from aminosalicylates to biological therapy. Tumor necrosis factor (TNF) alpha inhibitors were the first class of biological therapy approved for IBD. However, some patients do not respond to treatment (primary non-responders) or lose response over time (secondary loss of response). With a different mechanism of action, the class of anti-integrin monoclonal antibodies, represented by natalizumab and vedolizumab, has recently expanded. Vedolizumab is a gut selective anti-integrin that binds to the alfa4beta7 integrin, preventing its coupling to the endothelial MadCAM-1. In this way, it reduces the process of lymphocyte migration and reduces intestinal tissue inflammation. Multicentric real life studies with vedolizumab in UC and CD showed the efficacy and safety of the drug. More recently, a head-to-head trial comparing the efficacy of vedolizumab against adalimumab in UC demonstrated superiority of vedolizumab in comparison to the subcutaneous anti-TNF agent, defining positioning of the drug as an adequate first option in therapeutic sequencing. There is no head to head trial comparing vedolizumab against other agents in CD. Indeed, there is a lack of studies on the use of vedolizumab in CD in Brazil, mostly in biologic naïve patients, where the drug seems to have a more adequate therapeutic potential.

OBJECTIVES:

1. Primary objective: to analyze clinical remission rates [defined as a Harvey-Bradshaw index (HBI) of equal or lower than 4 for Crohn's disease (CD)] at weeks 12, 26 and 52, and at last follow-up.

2. Secondary objectives: to analyze clinical response rates (defined as a reduction at the HBI of equal or more than 3 points for CD and according to physician global assessment - PGA) at weeks 12, 26 and 52, and at last follow-up; to analyze endoscopic remission rates (defined as absence of ulcers in CD) in colonoscopies performed; to analyze persistence of drug therapy over time; to analyze adverse events during treatment with vedolizumab and rates of abdominal surgery during therapy.

METHODS: This project is already approved by the Institutional Review Board (IRB) from the Catholic University of Paraná, Brasil. A retrospective, longitudinal, observational study will be performed with patients with CD who used Vedolizumab at any time of their treatment as the first biologic option, after failure of conventional therapy. Inclusion criteria: Patients with CD, who used vedolizumab as the first biological agent during medical treatment, after failure of conventional therapy (aminosalicylates, steroids and/or immunomodulators such as azathioprine and methotrexate). Exclusion criteria: Patients with UC, other causes of intestinal inflammation (ischemic or infectious colitis, for example) non-IBD related, IBD-undetermined not defined as CD or UC will be excluded from the analysis. Patients with vedolizumab who had previous exposure to anti-TNF agents will also be excluded. Pregnant and pediatric patients (less than 18 years old) will also be excluded. Following the induction dose of 300 mg at weeks 0, 2 and 6, and maintenance of 300 mg every 8 weeks, patients will be followed up to 52 weeks (1 year) or more (last follow-up captured). Records of the clinical evaluations at week 12, 26 and 52, and last follow-up, will be checked according to the HBI for CD, and PGA to define clinical response or clinical remission. Colonoscopies will also be checked to evaluate mucosal healing.

Conditions

Crohn Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Study group

All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)

Vedolizumab

Intervention Type: DRUG

Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.

Interventions

Vedolizumab

Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with CD (any location)who used vedolizumab as the first biological agent during medical treatment, after failure of conventional therapy (5-ASA, steroids and/or immunomodulators such as azathioprine and methotrexate).

Exclusion Criteria

• Patients with UC
• Patients with other causes of intestinal inflammation (ischemic or infectious colitis, for example) non-IBD related
• Patients with IBD-undetermined not defined as CD or UC
• Patients with vedolizumab who had previous exposure to anti-TNF agents
• Pregnant patients
• Pediatric patients (less than 18 years old)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: collaborator

Pontifícia Universidade Católica do Paraná

OTHER

Sponsor Role: lead

Responsible Party

Roberto Pecoits-Filho

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Paulo Kotze, phd

Role: PRINCIPAL_INVESTIGATOR

Professor of postgraduate program

Central Contacts

Paulo Kotze, phd

Role: CONTACT

pgkotze@hotmail.com

+5541996648989

References

Perin RL, Damiao AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, Moraes AC, Nones RB, Teixeira FV, Zeroncio M, Kotze PG. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. Arq Gastroenterol. 2019 Sep 30;56(3):312-317. doi: 10.1590/S0004-2803.201900000-58. eCollection 2019.

Reference Type: RESULT

PMID: 31633731 (View on PubMed)

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155.

Reference Type: RESULT

PMID: 29788318 (View on PubMed)

Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018 Sep;53(9):1048-1064. doi: 10.1007/s00535-018-1480-0. Epub 2018 Jun 4.

Reference Type: RESULT

PMID: 29869016 (View on PubMed)

Other Identifiers

IISR-2020-103104

Identifier Type: -

Identifier Source: org_study_id